Eylea(aflibercept)
Ahzantive, Enzeevu, Eylea, Opuviz, Pavblu, Yesafili, Zaltrap (aflibercept) is a protein pharmaceutical. Aflibercept was first approved as Eylea on 2011-11-18. It is used to treat diabetic retinopathy and macular edema in the USA. It has been approved in Europe to treat colorectal neoplasms, degenerative myopia, diabetes complications, diabetic retinopathy, and macular edema amongst others. The pharmaceutical is active against vascular endothelial growth factor A, long form.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Enzeevu, Eylea, Opuviz, Pavblu, Yesafili, Zaltrap
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Aflibercept
Tradename | Proper name | Company | Number | Date | Products |
|---|---|---|---|---|---|
| Eylea | aflibercept | Regeneron Pharmaceuticals | N-125387 RX | 2011-11-18 | 2 products |
| Eylea HD | aflibercept | Regeneron Pharmaceuticals | N-761355 RX | 2023-08-18 | 1 products |
| Zaltrap | Ziv-Aflibercept | Sanofi | N-125418 RX | 2012-08-03 | 2 products |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| ahzantive | Biologic Licensing Application | 2025-10-27 |
| eydenzelt | Biologic Licensing Application | 2025-10-17 |
| eylea | Biologic Licensing Application | 2024-10-10 |
| eylea hd | Biologic Licensing Application | 2024-10-16 |
| opuviz | Biologic Licensing Application | 2024-12-19 |
| pavblu | Biologic Licensing Application | 2025-03-04 |
| zaltrap | Biologic Licensing Application | 2025-10-06 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| macular edema | — | D008269 | — |
| diabetic retinopathy | EFO_0003770 | D003930 | — |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
aflibercept, Eylea, Regeneron Pharmaceuticals, Inc. | |||
| 2030-02-08 | Orphan excl. | ||
Patent Expiration
No data
ATC Codes
L: Antineoplastic and immunomodulating agents
— L01: Antineoplastic agents
— L01X: Other antineoplastic agents in atc
— L01XX: Other antineoplastic agents in atc
— L01XX44: Aflibercept
S: Sensory organ drugs
— S01: Ophthalmologicals
— S01L: Ocular vascular disorder agents
— S01LA: Antineovascularisation agents
— S01LA05: Aflibercept
Clinical
Clinical Trials
572 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Macular degeneration | D008268 | EFO_0001365 | H35.30 | 1 | 3 | 9 | 11 | 25 | 49 |
| Macular edema | D008269 | — | — | — | 4 | 9 | 8 | 10 | 30 |
| Edema | D004487 | — | R60.9 | — | 2 | 7 | 4 | 4 | 17 |
| Wet macular degeneration | D057135 | EFO_0004683 | — | — | — | 2 | 5 | 9 | 16 |
| Retinal vein occlusion | D012170 | EFO_1001157 | H34.81 | — | — | 4 | 1 | 7 | 12 |
| Choroidal neovascularization | D020256 | — | — | — | 1 | 1 | 1 | 3 | 6 |
| Pathologic neovascularization | D009389 | — | — | — | — | 1 | 1 | 3 | 5 |
| Polypoidal choroidal vasculopathy | D000092342 | — | — | — | — | — | 4 | 1 | 5 |
| Vascular diseases | D014652 | EFO_0004264 | I77 | — | — | — | 3 | 1 | 4 |
| Diabetic retinopathy | D003930 | EFO_0003770 | — | — | — | — | 1 | 1 | 2 |
Show 1 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Retinal diseases | D012164 | — | H35.9 | — | — | 3 | — | 1 | 4 |
| Retinopathy of prematurity | D012178 | EFO_1001158 | H35.1 | — | — | 2 | — | 2 | 4 |
| Eye diseases | D005128 | EFO_0003966 | H44 | — | — | 2 | — | 1 | 3 |
| Neovascular glaucoma | D015355 | EFO_1001060 | — | — | — | 2 | — | 1 | 3 |
| Myopia | D009216 | EFO_0003927 | H52.1 | — | — | 1 | — | 1 | 2 |
| Vision disorders | D014786 | — | H53.11 | — | — | 1 | — | 1 | 2 |
| Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | — | 1 | 2 | — | — | 2 |
| Glaucoma | D005901 | EFO_0000516 | H40 | — | — | 2 | — | — | 2 |
| Neoplasm metastasis | D009362 | EFO_0009708 | — | — | — | 2 | — | — | 2 |
| Retinal degeneration | D012162 | — | — | — | — | 1 | — | — | 1 |
Show 5 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Colorectal neoplasms | D015179 | — | — | — | 1 | — | — | — | 1 |
| Retinitis pigmentosa | D012174 | — | H35.52 | — | 1 | — | — | — | 1 |
| Retinitis | D012173 | — | H30.9 | — | 1 | — | — | — | 1 |
Indications Phases 1
No data
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Retinal neovascularization | D015861 | — | H35.05 | — | — | — | — | 1 | 1 |
| Caregiver burden | D000084802 | — | — | — | — | — | — | 1 | 1 |
| Newborn infant diseases | D007232 | — | — | — | — | — | — | 1 | 1 |
| Uveitis | D014605 | EFO_1001231 | H20.9 | — | — | — | — | 1 | 1 |
| Inflammation | D007249 | MP_0001845 | — | — | — | — | — | 1 | 1 |
| Endophthalmitis | D009877 | — | — | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Aflibercept |
| INN | aflibercept |
| Description | Aflibercept, sold under the brandname Eylea and Zaltrap, is a medication used to treat wet macular degeneration and metastatic colorectal cancer. It was developed by Regeneron Pharmaceuticals and is approved in the United States and Europe.
|
| Classification | Protein |
| Drug class | receptor molecules or membrane ligands, natural, modified or modified: vascular endothelial growth factor (VEGF) receptors |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL1742982 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB08885 |
| UNII ID | 15C2VL427D (ChemIDplus, GSRS) |
Target
Agency Approved
VEGFA
VEGFA
Organism
Homo sapiens
Gene name
VEGFA
Gene synonyms
VEGF
NCBI Gene ID
Protein name
vascular endothelial growth factor A, long form
Protein synonyms
vascular endothelial growth factor A121, vascular endothelial growth factor A165, Vascular permeability factor, VPF
Uniprot ID
Mouse ortholog
Vegfa (22339)
vascular endothelial growth factor A, long form (Q6WZL9)
Alternate
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Eylea – Regeneron Pharmaceuticals
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Zaltrap – Regeneron Pharmaceuticals
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 13,061 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
29,478 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use